ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.448,98
-0,41%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Quoin Pharmaceuticals Ltd (QNRX)

  7. Quoin Pharmaceuticals Ltd (QNRX) News

QNRX

Quoin Pharmaceuticals (QNRX)

Quoin Pharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:QNRX
DatumZeitQuelleÜberschriftSymbolFirma
10/05/202422h10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
09/05/202414h30GlobeNewswire Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
08/05/202422h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
02/05/202422h10GlobeNewswire Inc.Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:QNRXQuoin Pharmaceuticals Ltd
13/03/202421h05GlobeNewswire Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
13/03/202412h03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:QNRXQuoin Pharmaceuticals Ltd
08/03/202422h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
08/03/202422h04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
08/03/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
07/03/202422h05GlobeNewswire Inc.Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETNASDAQ:QNRXQuoin Pharmaceuticals Ltd
06/03/202423h07Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
06/03/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
05/03/202414h00GlobeNewswire Inc.Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public OfferingNASDAQ:QNRXQuoin Pharmaceuticals Ltd
04/03/202423h27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
04/03/202414h00GlobeNewswire Inc.Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical StudiesNASDAQ:QNRXQuoin Pharmaceuticals Ltd
27/02/202412h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
15/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QNRXQuoin Pharmaceuticals Ltd
14/02/202402h11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
13/02/202422h50Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
13/02/202422h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
12/02/202423h12Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:QNRXQuoin Pharmaceuticals Ltd
08/02/202414h00GlobeNewswire Inc.Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination ProductNASDAQ:QNRXQuoin Pharmaceuticals Ltd
30/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
18/12/202323h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
18/12/202323h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
13/12/202314h30GlobeNewswire Inc.Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeNASDAQ:QNRXQuoin Pharmaceuticals Ltd
09/11/202323h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
09/11/202323h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNRXQuoin Pharmaceuticals Ltd
09/11/202323h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNRXQuoin Pharmaceuticals Ltd
08/11/202323h46GlobeNewswire Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:QNRXQuoin Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:QNRX

Kürzlich von Ihnen besucht

LSE
74AL
First.abu 26
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten